A Randomized Trial of Shunting for Idiopathic Normal-Pressure Hydrocephalus

Name: Αlpha¹ Rigor Record — A Randomized Trial of Shunting for Idiopathic Normal-Pressure Hydrocephalus
Item: A Randomized Trial of Shunting for Idiopathic Normal-Pressure Hydrocephalus
Rating: 59
Author: Αlpha¹

Luciano MG, Williams MA, Hamilton MG, Katzen HL, Dasher NA, Moghekar A, Hua J, Malm J, Eklund A, Alpert Abel N, Raslan AM, Elder BD, Savage JJ, Barrow DL, Shahlaie K, Jensen H, Zwimpfer TJ, Wollett J, Hanley DF, Holubkov R, PENS Trial Investigators and the Adult Hydrocephalus Clinical Research Network.

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 4★ (Strong), 0 critical, 3 high issues for “A Randomized Trial of Shunting for Idiopathic Normal-Pressure Hydrocephalus”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

4 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

ReportingData & code availability not met−0.5★
ReportingEthical approvals partially met−0.25★
ReportingKey resources partially met−0.25★

Model-reported confidence: moderateReviewer agreement: highEngine: 7.29.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run on this paper: the pass that reads its reported means did not complete. No reported mean was checked for arithmetic impossibility.

Problems surfaced4 types

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps3

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data and code not sharedAssessed
Ethics/consent reporting incompleteAssessed
Key resources under-identified (antibodies, cell lines, RRIDs)Assessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a methodologically strong, well-powered, double-blind placebo-controlled RCT of shunt surgery for iNPH, with a clear scientific rationale, robust design, adequate biological-variable reporting, consistent recomputation of the 7 machine-checkable statistics, and transparent reporting of outcomes, limitations, funding, and COI. The main weaknesses are the complete absence of a data availability statement (a fail) and under-specification of the randomization method, analysis software, and an explicit regulatory-compliance framework (warn-level gaps).

Both reviewers were synthesized per dimension; they agreed on 7 of 8 statuses and diverged only on ethical approvals (warn vs pass), which I resolved to warn while preserving the pass-dissenter's evidence. Statistics verification covered only the 7 tests reported with test statistic + df or effect + CI — everything else (including 'NS' p-values) is unverified, not confirmed. No retracted or unresolvable references (44 checked); both reproducibility links are live; the trial is registered (ClinicalTrials.gov NCT05081128).

8 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 7 tests: 7 consistent, 0 inconsistent; 7 via agent-written checks.

Reporting

Eight Dimensions5 pass · 2 warn · 1 fail

The introduction cites the 2005 International iNPH Guidelines, the Japanese Guidelines, previous small trials, and a 2024 Cochrane review noting the need for larger studies. It acknowledges skepticism about shunt effectiveness and a call for a moratorium. The study objectives directly follow from these gaps.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper clearly establishes the scientific premise, cites prior studies and guidelines, and justifies the need for an adequately powered randomized placebo-controlled trial.

Evidence

direct quote[Introduction]

“a 2024 Cochrane review noted, “there is a need for similar studies to increase the certainty of the findings presented””